NeOnc Technologies Holdings (NTHI) Q2 2026 earnings summary

Executive summary

• Focused on developing novel drug delivery methods for brain cancers, with lead candidates NEO100 and NEO212 in clinical and preclinical stages; completed topline analysis of fully enrolled Phase 2a NEO100 study in recurrent IDH1-mutant high-grade glioma, with results to be presented August 12, 2026.

• Secured UAE IND approvals for both NEO100 and NEO212, expanding international clinical development alongside ongoing U.S. programs.

• No product revenue; operations funded by equity and debt financings, including PIPE and Series A Preferred Stock in 2026.

• Net loss of $14.2M for Q2 2026 and $23.1M for the first half of 2026; accumulated deficit reached $135.8M.

• Substantial doubt exists about ability to continue as a going concern without additional capital.

Financial highlights

• Q2 2026 operating expenses: $2.65M R&D, $1.29M legal/professional, $0.90M G&A, $5.65M stock-based compensation, $3.59M advisory fees; R&D expenses rose from $0.7M to $2.6M year-over-year.

• Net loss per share: $(0.58) for Q2 2026, $(0.96) for the first half of 2026.

• Cash at June 30, 2026: $2.0M; net cash used in operations for H1 2026: $11.8M.

• Financing activities in H1 2026 provided $13.7M, mainly from PIPE and Series A Preferred Stock.

• Approximately 40% of total operating expenses ($5.7M of $14.1M) were noncash stock-based compensation.

Outlook and guidance

• Expects continued operating losses as clinical programs advance; no product revenue anticipated for several years.

• Topline Phase 2a results for NEO100 in recurrent IDH1-mutant high-grade glioma to be presented August 12, 2026.

• Incorporating FDA feedback into the proposed Phase 2 development strategy for NEO212, with official meeting minutes expected in August 2026.

• Plans to finance operations through available credit lines, equity purchase agreements, and potential ATM offerings.

• Additional funding required to sustain operations beyond the next 12 months.